IDEAYA Biosciences vs Nuvation Bio
IDYA and NUVB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IDYA and NUVB compare
IDEAYA Biosciences is the larger company, worth 2.2 times as much as Nuvation Bio ($3.1B against $1.4B).
Nuvation Bio keeps more of each dollar of sales as profit, with a net margin of −67.4% compared with −74.8% at IDEAYA Biosciences.
IDEAYA Biosciences scores higher on the StockData Score (9 against 4 for Nuvation Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IDYA | NUVB |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $1.4B |
| Share price | $31.83 | $3.99 |
| Change, 1 year | −0.38% | −19.1% |
| Change, 5 years | 37.1% | −55.9% |
| Beta (5Y) | 0.78 | 1.45 |
| Employees | 145 | 298 |
| StockData Score | ||
| Total score | 9 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 13.1× | 6.9× (better) |
| P/B | 2.6× (better) | 6.1× |
| FCF yield | −3.7% | – |
| Fair value | $29.10 | $1.94 |
| Margin of safety | −9.4% (better) | −105% |
| Growth | ||
| Revenue growth (TTM) | – | 654% |
| Revenue growth, 5Y average | 62.1% | – |
| Profitability | ||
| Operating margin | −92.7% | −61.2% (better) |
| Net margin | −74.8% | −67.4% (better) |
| FCF margin | −48.6% | – |
| Return on equity | −16.2% (better) | −49.1% |
| Return on invested capital | −51.9% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.03 (better) |
| Interest coverage | – | −5.9× |
| Current ratio | 10.45 (better) | 7.45 |
| Altman Z-score | 15.97 (better) | 0.06 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 106% | 66.5% |
| Held by insiders | 0.83% | 24.6% |
| Insider net buying, 12 months | $281K (better) | −$4.5M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 8.6% | 23.4% |
Go deeper
- IDYA stock overview
- IDYA income statement
- IDYA valuation and score
- NUVB stock overview
- NUVB income statement
- NUVB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.